Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Sugammadex Reversal of Pipecuronium vs Rocuronium in Anesthesia
NCT07044180Phase 4Active, not recruiting
- Start
- Jun 2025
- Primary completion
- Dec 2028
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised trial of pipecuronium in neuromuscular blockade (NMB) (2 arms). Primary endpoint: Time from administration of reversal agent to Train-of-Four (TOF) ratio of 0.9. Started Jun 2025; status: active, not recruiting.
02
Drugs
pipecuronium
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT07044180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07044180.